Wide‑ranging analysis of survival‑related alternative splicing events in invasive breast carcinoma

Jia,Keren; Wu,Yingcheng; Huang,Jing; Chen,Jianing; Wei,Huagen; Wu,Huiqun

doi:10.3892/ol.2020.11695

Wide‑ranging analysis of survival‑related alternative splicing events in invasive breast carcinoma

Authors:
- Keren Jia
- Yingcheng Wu
- Jing Huang
- Jianing Chen
- Huagen Wei
- Huiqun Wu
View Affiliations

Affiliations: School of Medicine, Nantong University, Nantong, Jiangsu 226001, P.R. China, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China, Department of Medical Informatics, Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/ol.2020.11695
Pages: 1866-1878
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Invasive breast carcinoma (BRCA) is a serious disease that threatens the survival time of those affected. Alternative splicing (AS) involved in BRCA pathogenesis may be a potential therapeutic target. However, to the best of our knowledge, a systematic analysis of survival‑related alternative splicing events (SREs) has not yet been reported. The aim of the present study was to identify SREs and analyze their potential biological functions as BRCA prognostic biomarkers. An UpSet plot demonstrated AS global characteristics. Cox's proportional hazards regression model quantitatively demonstrated the prognostic relevance of AS events. Functional enrichment analysis investigated the potential pathways through which AS events affect BRCA progression. The receiver operating characteristic curve model determined the clinical significance of AS events represented using percent‑spliced‑in (PSI) values. The regulatory network of splicing factors (SFs) and AS events laid the foundation for studying the role of SFs in BRCA. The present study identified 1,215 SREs and their distribution characteristics, suggesting that AS events in exon skipping (ES) primarily exerted normal physiological functions, while AS events in alternative terminator sites had the most significant prognostic effect. The present study demonstrated that survival‑associated genes are involved primarily in certain biological processes of ribosomal proteins. In the diagnostic model, the alternative acceptor site, alternative donor site, alternative promoter site and ES performed well. ELAVL4 was the key gene associated with prognosis and SREs. In conclusion, a number of AS events affect BRCA initiation, progression and prognosis. The PSI value of AS events has the potential to diagnose BRCA and predict a prognosis; however, this must be confirmed in additional studies.

View Figures

View References

1	Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, Mellemkjær L, Czene K and Hartman M: Incidence and outcome of male breast cancer: An international population-based study. J Clin Oncol. 29:4381–4386. 2011. View Article : Google Scholar : PubMed/NCBI
2	Coughlin SS: Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 177:537–548. 2019. View Article : Google Scholar : PubMed/NCBI
3	San Miguel Y, Gomez SL, Murphy JD, Schwab RB, McDaniels-Davidson C, Canchola AJ, Molinolo AA, Nodora JN and Martinez ME: Age-related differences in breast cancer mortality according to race/ethnicity, insurance, and socioeconomic status. BMC Cancer. 20:2282020. View Article : Google Scholar
4	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
6	Black DL: Protein diversity from alternative splicing: A challenge for bioinformatics and post-genome biology. Cell. 103:367–370. 2000. View Article : Google Scholar : PubMed/NCBI
7	Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, Sun S, Yang F, Shen YA, Murray RR, et al: Widespread expansion of protein interaction capabilities by alternative splicing. Cell. 164:805–817. 2016. View Article : Google Scholar : PubMed/NCBI
8	Parikshak NN, Swarup V, Belgard TG, Irimia M, Ramaswami G, Gandal MJ, Hartl C, Leppa V, Ubieta LT, Huang J, et al: Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature. 540:423–427. 2016. View Article : Google Scholar : PubMed/NCBI
9	Read A and Natrajan R: Splicing dysregulation as a driver of breast cancer. Endocr Relat Cancer. 25:R467–R478. 2018. View Article : Google Scholar : PubMed/NCBI
10	Tian N, Li J, Shi J and Sui G: From general aberrant alternative splicing in cancers and its therapeutic application to the discovery of an oncogenic DMTF1 isoform. Int J Mol Sci. 18:E1912017. View Article : Google Scholar : PubMed/NCBI
11	Tien JF, Mazloomian A, Cheng SG, Hughes CS, Chow CCT, Canapi LT, Oloumi A, Trigo-Gonzalez G, Bashashati A, Xu J, et al: CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 45:6698–6716. 2017. View Article : Google Scholar : PubMed/NCBI
12	Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, et al: Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci USA. 115:E3426–E3435. 2018. View Article : Google Scholar : PubMed/NCBI
13	Climente-González H, Porta-Pardo E, Godzik A and Eyras E: The functional impact of alternative splicing in cancer. Cell Rep. 20:2215–2226. 2017. View Article : Google Scholar : PubMed/NCBI
14	Martinez-Montiel N, Rosas-Murrieta NH, Anaya Ruiz M, Monjaraz-Guzman E and Martinez-Contreras R: Alternative splicing as a target for cancer treatment. Int J Mol Sci. 19:E5452018. View Article : Google Scholar : PubMed/NCBI
15	Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 44:D1018–D1022. 2016. View Article : Google Scholar : PubMed/NCBI
16	Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES and Cardoso F: Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res Treat. 173:37–48. 2019. View Article : Google Scholar : PubMed/NCBI
17	RStudio Team (2015), . RStudio: Integrated Development for R. RStudio, Inc. (Boston, MA). 2015.
18	R Core Team, . 2012.R: A language and environment for statistical computing. R Foundation for Statistical Computing. (Vienna, Austria, 2012).
19	Conway JR, Lex A and Gehlenborg N: UpSetR: An R package for the visualization of intersecting sets and their properties. Bioinformatics. 33:2938–2940. 2017. View Article : Google Scholar : PubMed/NCBI
20	The Gene Ontology Consortium, . Expansion of the gene ontology knowledgebase and resources. Nucleic Acids Res. 45:D331–D338. 2017. View Article : Google Scholar : PubMed/NCBI
21	Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, et al: The reactome pathway knowledgebase. Nucleic Acids Res. 46:D649–D655. 2018. View Article : Google Scholar : PubMed/NCBI
22	Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and Galon J: ClueGO: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
23	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
24	Sahebi M, Hanafi MM, van Wijnen AJ, Azizi P, Abiri R, Ashkani S and Taheri S: Towards understanding pre-mRNA splicing mechanisms and the role of SR proteins. Gene. 587:107–119. 2016. View Article : Google Scholar : PubMed/NCBI
25	Piva F, Giulietti M, Burini AB and Principato G: SpliceAid 2: A database of human splicing factors expression data and RNA target motifs. Hum Mutat. 33:81–85. 2012. View Article : Google Scholar : PubMed/NCBI
26	Woolston C: Breast cancer. Nature. 527:S1012015. View Article : Google Scholar : PubMed/NCBI
27	Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R and White KP: Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 13:e10065892017. View Article : Google Scholar : PubMed/NCBI
28	Kim SY, Kawaguchi T, Yan L, Young J, Qi Q and Takabe K: Clinical relevance of microRNA expressions in breast cancer validated using the cancer genome atlas (TCGA). Ann Surg Oncol. 24:2943–2949. 2017. View Article : Google Scholar : PubMed/NCBI
29	Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, et al: The molecular basis of breast cancer pathological phenotypes. J Pathol. 241:375–391. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP and Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature. 456:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
31	Biamonti G, Catillo M, Pignataro D, Montecucco A and Ghigna C: The alternative splicing side of cancer. Semin Cell Dev Biol. 32:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
32	Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom KJ, Salmon A, D'Silva O, Betteridge KB, et al: Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Mol Oncol. 9:167–178. 2015. View Article : Google Scholar : PubMed/NCBI
33	Xiong Y, Deng Y, Wang K, Zhou H, Zheng X, Si L and Fu Z: Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data. EBioMedicine. 36:183–195. 2018. View Article : Google Scholar : PubMed/NCBI
34	Lin P, He RQ, Ma FC, Liang L, He Y, Yang H, Dang YW and Chen G: Systematic analysis of survival-associated alternative splicing signatures in gastrointestinal pan-adenocarcinomas. EBioMedicine. 34:46–60. 2018. View Article : Google Scholar : PubMed/NCBI
35	Zhang R, Lin P, Yang X, He RQ, Wu HY, Dang YW, Gu YY, Peng ZG, Feng ZB and Chen G: Survival associated alternative splicing events in diffuse large B-cell lymphoma. Am J Transl Res. 10:2636–2647. 2018.PubMed/NCBI
36	Zahler AM, Lane WS, Stolk JA and Roth MB: SR proteins: A conserved family of pre-mRNA splicing factors. Genes Dev. 6:837–847. 1992. View Article : Google Scholar : PubMed/NCBI
37	Kedzierska H and Piekielko-Witkowska A: Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 396:53–65. 2017. View Article : Google Scholar : PubMed/NCBI
38	Mahiet C and Swanson CM: Control of HIV-1 gene expression by SR proteins. Biochem Soc Trans. 44:1417–1425. 2016. View Article : Google Scholar : PubMed/NCBI
39	Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG and Harbour JW: Driver mutations in uveal melanoma: Associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 134:728–733. 2016. View Article : Google Scholar : PubMed/NCBI
40	Hu Y, Sun Z, Deng J, Hu B, Yan W, Wei H and Jiang J: Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway. Tumour Biol. 39:10104283176943182017. View Article : Google Scholar : PubMed/NCBI
41	Koedoot E, Fokkelman M, Rogkoti VM, Smid M, van de Sandt I, de Bont H, Pont C, Klip JE, Wink S, Timmermans MA, et al: Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes. Nat Commun. 10:29832019. View Article : Google Scholar : PubMed/NCBI
42	Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, Atfi A, Watabe K, Lu Z and Mo YY: Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 7:e22622016. View Article : Google Scholar : PubMed/NCBI
43	Oltean S and Bates DO: Hallmarks of alternative splicing in cancer. Oncogene. 33:5311–5318. 2014. View Article : Google Scholar : PubMed/NCBI
44	Feng W, Liang C, Wang C, Yu X, Li Q and Yang H: Knockdown of ribosomal protein S15A inhibits proliferation of breast cancer cells through induction of apoptosis in vitro. Cytotechnology. 70:1315–1323. 2018. View Article : Google Scholar : PubMed/NCBI
45	Thakur A, Sun Y, Bollig A, Wu J, Biliran H, Banerjee S, Sarkar FH and Liao DJ: Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin Cancer Res. 14:4427–4436. 2008. View Article : Google Scholar : PubMed/NCBI
46	Zhu J, Li QY, Liu JL, Wei W, Yang HW and Tang W: RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. Oncol Rep. 34:3156–3162. 2015. View Article : Google Scholar : PubMed/NCBI
47	Ono H, Iizumi Y, Goi W, Sowa Y, Taguchi T and Sakai T: Ribosomal protein S3 regulates XIAP expression independently of the NF-kB pathway in breast cancer cells. Oncol Rep. 38:3205–3210. 2017. View Article : Google Scholar : PubMed/NCBI
48	Wang F, Lu J, Li S, Huo X, Liu X, Du X, Li C, Wang J and Chen Z: Application of serum ELAVL4 (HuD) antigen assay for small cell lung cancer diagnosis. Anticancer Res. 37:4515–4522. 2017.PubMed/NCBI
49	Wong KK, Rostomily R and Wong STC: Prognostic gene discovery in glioblastoma patients using deep learning. Cancers (Basel). 11:E532019. View Article : Google Scholar : PubMed/NCBI